

# BEST AVAILABLE COPY

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

|   |    |  |
|---|----|--|
| (51) International Patent Classification <sup>6</sup> :<br><b>A61K 9/00, 9/12, 31/21, B65D 83/38</b>  | A1 | (11) International Publication Number: <b>WO 97/09034</b><br>(43) International Publication Date: 13 March 1997 (13.03.97)   |
| (21) International Application Number: <b>PCT/GB96/02174</b>  |    | (81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). |
| (22) International Filing Date: 4 September 1996 (04.09.96)   |    |  |
| (30) Priority Data:<br>9517998.2 4 September 1995 (04.09.95) GB   |    |  |
| (71) Applicant (for all designated States except US): BIOGLAN LABORATORIES LTD. [GB/GB]; 5 Hunting Gate, Hitchin, Hertfordshire SG4 0TJ (GB). |    |  |
| (72) Inventor; and  |    | Published  |
| (75) Inventor/Applicant (for US only): GOODMAN, Michael [GB/GB]; 30 Rushbrook Close, Ampthill, Bedfordshire MK45 2XE (GB).                    |    | With international search report.<br>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.  |
| (74) Agents: JUMP, Timothy, John, Simon et al.; Venner, Shipley & Co., 20 Little Britain, London EC1A 7DH (GB).                               |    |  |

**(54) Title: PHARMACEUTICAL COMPOSITIONS AND DEVICES FOR THEIR ADMINISTRATION**

**(57) Abstract**

A device for providing pharmaceutical doses comprising a container, filled with a pharmaceutical composition including glyceryl trinitrate and 1,1,1,2-tetrafluoroethane (HFC-134a) or 1,1,1,2,3,3-heptafluoropropane (HFC-227) as a propellant, and valve means arranged for delivering aerosol doses of said pharmaceutical composition to the exterior of the container, wherein at least a portion of the device is formed from a polyester. Compositions for use in such devices are also described.



***FOR THE PURPOSES OF INFORMATION ONLY***

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

|    |                          |    |  |    |                          |
|----|--------------------------|----|--|----|--------------------------|
| AM | Armenia                  | GB | United Kingdom                           | MW | Malawi                   |
| AT | Austria                  | GE | Georgia                                  | MX | Mexico                   |
| AU | Australia                | GN | Guinea                                   | NE | Niger                    |
| BB | Barbados                 | GR | Greece                                   | NL | Netherlands              |
| BE | Belgium                  | HU | Hungary                                  | NO | Norway                   |
| BF | Burkina Faso             | IE | Ireland                                  | NZ | New Zealand              |
| BG | Bulgaria                 | IT | Italy                                    | PL | Poland                   |
| BJ | Benin                    | JP | Japan                                    | PT | Portugal                 |
| BR | Brazil                   | KE | Kenya                                    | RO | Romania                  |
| BY | Belarus                  | KG | Kyrgyzstan                               | RU | Russian Federation       |
| CA | Canada                   | KP | Democratic People's Republic<br>of Korea | SD | Sudan                    |
| CF | Central African Republic | KR | Republic of Korea                        | SE | Sweden                   |
| CG | Congo                    | KZ | Kazakhstan                               | SG | Singapore                |
| CH | Switzerland              | LI | Liechtenstein                            | SI | Slovenia                 |
| CI | Côte d'Ivoire            | LK | Sri Lanka                                | SK | Slovakia                 |
| CM | Cameroon                 | LR | Liberia                                  | SN | Senegal                  |
| CN | China                    | LT | Lithuania                                | SZ | Swaziland                |
| CS | Czechoslovakia           | LU | Luxembourg                               | TD | Chad                     |
| CZ | Czech Republic           | LV | Latvia                                   | TG | Togo                     |
| DE | Germany                  | MC | Monaco                                   | TJ | Tajikistan               |
| DK | Denmark                  | MD | Republic of Moldova                      | TT | Trinidad and Tobago      |
| EE | Estonia                  | MG | Madagascar                               | UA | Ukraine                  |
| ES | Spain                    | ML | Mali                                     | UG | Uganda                   |
| FI | Finland                  | MN | Mongolia                                 | US | United States of America |
| FR | France                   | MR | Mauritania                               | UZ | Uzbekistan               |
| GA | Gabon                    |    |  | VN | Viet Nam                 |

- 1 -

PHARMACEUTICAL COMPOSITIONS AND DEVICES FOR  
THEIR ADMINISTRATION

5

DESCRIPTION

The present invention relates to a pharmaceutical composition comprising glyceryl trinitrate for delivery in aerosol form and to a device for delivering such a  
10 composition as an aerosol.

Glyceryl trinitrate is well established in the treatment and prophylaxis of angina pectoris and, when used to relieve acute attacks, is most commonly  
15 administered lingually, sub-lingually or buccally in the form of a spray, buccal tablet or chewable lozenge. Absorption of glyceryl trinitrate via the oral mucosa, particularly the sub-lingual oral mucosa, is rapid and haemodynamic effects and relief from pain are almost  
20 immediate.

Current aerosol spray formulations of glyceryl trinitrate use one or more chlorofluorocarbon as a propellant; dichlorodifluoromethane being commonly  
25 used. However, chlorofluorocarbons have been implicated in the depletion of the ozone layer and their production, therefore, is being phased out. It has been found that certain hydrofluorocarbons, which

- 2 -

are both of low toxicity and of suitable vapour pressure for use as aerosol propellants, are significantly less harmful to the ozone layer. Among such hydrofluorocarbons, 1,1,1,2-tetrafluoroethane 5 (HFC-134a) and 1,1,1,2,3,3,3-heptafluoropropane (HFC-227) have been proposed as suitable propellants for pharmaceutical aerosols.

It has now been found that HFC-134a and HFC-227 can be 10 used in combination with glycetyl trinitrate, without causing any degradation of the latter or reduction in its physiological effect.

Devices for administering metered aerosol doses of 15 pharmaceutical preparations are well known in the art. Such devices include those disclosed in WO 92/11190, US-A-4819834, US-A-4407481. Many of these devices include metering valves having components formed from plastic materials, such as the valves available from 20 Bespak PLC of Bergen Way, Kings Lynn, Norfolk PE30 2JJ, United Kingdom, in which the valve core, metering chamber and some other structural components are formed from plastic materials. The plastic materials currently used for forming these structural parts in 25 valves employed with chlorofluorocarbon containing formulations of glycetyl trinitrate include certain acetal co-polymers.

- 3 -

Although the plastics employed to manufacture metering valves, including the aforementioned acetal copolymers, have also been found to be stable in the presence of HFC-134a alone, the applicants, to their surprise, have determined that many of these plastics materials can be caused to swell in the presence of formulations which include glycercyl trinitrate and HFC-134a. When such swelling takes place in a valve, the fit of mutually slid able components, such as metering chambers and valve cores, is adversely effected and they can bind together or become loose, causing the valve to leak or cease functioning altogether.

This problem was solved in accordance with a first aspect of the invention which provides a device for providing pharmaceutical doses, comprising a container, filled with a pharmaceutical composition including glycercyl trinitrate and 1,1,1,2-tetrafluoroethane (HFC-134a) or 1,1,1,2,3,3-heptafluoropropane (HFC-227) as a propellant, and valve means arranged for delivering aerosol doses of said pharmaceutical composition to the exterior of the container, wherein at least a portion of the device is formed from a polyester. Preferably, the valve means includes at least one component formed from a polyester which component, more preferably, is a metering chamber and/or a valve core. Preferably, devices in accordance with the invention are arranged to provide metered doses of glycercyl trinitrate.

- 4 -

In further embodiments, the container comprises a polyester and, preferably, consists of metal lined with a polyester. The canister cap can also be so formed.

5

Apart from allowing the aforementioned swelling problem to be avoided, an advantage of the present invention is that use of expensive metal valve components can be avoided.

10

During the course of the work leading to the present invention, tests carried out on glyceryl trinitrate/ethanol/HFC-134a filled metered dose aerosol devices, with acetyl copolymer or nylon valve components, showed that they failed to provide uniform doses after storage under controlled conditions. Such effects are normally associated with problems involving the gaskets or seals employed within the valve mechanisms. Thus, it came as a surprise to the applicants when they discovered that these failures were being caused by the valve components swelling to an unacceptable extent, particularly since at least one of the materials used to form them (acetyl co-polymer) was known to be stable in the presence of HFC-134a, either alone or in admixture with ethanol, or conventional glyceryl trinitrate/ethanol/chlorofluoro carbon formulations.

- 5 -

The preferred polyesters are polyalkylene benzene dicarboxylates, more preferably polyalkylene terephthalates and, most preferably, a polybutylene terephthalate.

5

Such materials, preferably, have a density of about 1.3g/cm<sup>3</sup> and a water absorption of about 0.6% (23°C saturation). The polyesters, also, are preferably partially crystalline in nature and have a crystalline 10 melting range of 220-225°C.

Examples of suitable polybutylene terephthalates include those available under the Trademark Celanex® from Hoechst UK Limited, Walton Manner, Milton Keynes, 15 Bucks MK7 7AJ, United Kingdom. Particularly preferred are Celanex® 2500 and Celanex® X 500/2.

The preferred propellant for use in the inventive device is HFC-134a and, in embodiments, the preparation 20 further comprises, as a co-solvent, a lower alkyl alcohol, preferably ethanol, or a pharmaceutically acceptable polyol, preferably propylene glycol, glycerol or polyethylene glycol. The preferred co-solvent is ethanol. The lower alkyl alcohols can be 25 C<sub>2</sub>-C<sub>4</sub> alkyl alcohols.

In embodiments, the composition included in the inventive device further comprises a flavouring oil,

- 6 -

preferably peppermint oil Ph Eur. In all embodiments, it is preferred that the composition within the device comprises a solution of the propellant, glyceryl trinitrate and any co-solvent and flavouring agent 5 employed.

In a second aspect, the invention provides a pharmaceutical composition for use in a device in accordance with the first aspect of the invention, 10 comprising glyceryl trinitrate and HFC-134a or HFC-227 as a propellant. The preferred propellant is HFC-134a and it is further preferred that ethanol is included in the preparation.

15 In preferred embodiments of the invention, pharmaceutical compositions for use in devices in accordance with the first aspect of the invention can comprise 75-95% w/w HFC-134a, or HFC-227 as a propellant, an optional amount of 0.5-2% w/w of a 20 flavouring oil, and 5-25% w/w of a combination of 2-8% w/w glyceryl trinitrate and 92-98% w/w of a lower alkyl alcohol or a pharmaceutically acceptable polyol as a co-solvent. An advantage of such embodiments is that, because they include a greater proportion of volatile 25 propellant than usual, the risk of a potentially clogging deposit of non-volatile material building up around the outlet nozzle of the device is minimised. This is particularly so in embodiments where no non-

- 7 -

volatile agents, other than the active agent and a minimal amount (as specified above) of flavouring oil, are included in the composition.

5 Preferably, the flavouring oil is peppermint oil. The preferred lower alcohol is ethanol and the preferred pharmaceutically acceptable polyols are propylene glycol, glycerol and polyethylene glycol.  
It is preferred that compositions in accordance with  
10 the second aspect of the invention are in the form of liquid solutions, when maintained under pressure in devices in accordance with the first aspect of the invention, and are especially suited to use therein, since they do not cause significant degradation of the  
15 valve components employed in such devices.

Further excipients can be included in the formulations employed in the present invention. For example, neutral oils and surfactants (the latter for aiding the  
20 smooth operation of the valve), as are well known to those skilled in the art, may be included.

In a third aspect, the invention provides the use of a polyester in contact with a composition comprising  
25 glyceryl trinitrate, HFC-134a and/or HFC-227. Preferably the composition is in accordance with the second aspect of the invention, the polyester is one of those described above, and the use takes place in a

- 8 -

metered dose dispensing aerosol device.

An embodiment of the first aspect of the present invention will now be described, by way of example 5 only, and with reference to the following drawing.

Figure 1 is a cross sectional view of an embodiment of a device in accordance with the invention.

10 The device 1 comprises a substantially cylindrical canister 2 sealed with a cap 3. Both the canister 2 and the cap 3 are formed from an aluminium alloy and can be lined with a polyester (such as Celanex® 2500) or a lacquer (not shown).

15

A valve body moulding 4 comprises a cylindrical portion 5, which defines a metering chamber 6 and a stepped flange portion 7, and is formed by injection moulding from Celanex® 2500. The stepped flange portion 7

20 defines a first and outwardly facing annular seat 8 and a second, inwardly facing annular seat 9. The first annular seat 8 accommodates an annular sealing ring 10 and the second annular seat 9 accommodates a first sealing washer 11. The first sealing washer 11 is 25 located so as to cooperate with the cylindrical portion 5 of the valve body moulding 4, in defining the metering chamber 6.

- 9 -

A base 12 of the cylindrical portion 5 of the valve body moulding 4 completes the boundary to the metering chamber 6 and provides a seat for a second sealing washer 13.

5

The sealing ring 10 and the first and second sealing washers 11 and 13 can be formed from a butyl rubber, neoprene or one of the elastomers disclosed for such purposes in WO 92/11190.

10

An elongate, substantially cylindrical and partially hollow valve core 14 is slidably located within the first and second sealing washers 11 and 13 and extends through an orifice 15, defined in the base 12. The 15 valve core 14 is formed by injection moulding from Celanex® 2500.

A stepped inlet passage 16 communicates between a first end 17 of the valve core 14 and an inlet orifice 18, 20 formed through the side of the valve core 14. In a likewise manner, an outlet passage 19 communicates between the second end 20 of the valve core 14 and an outlet orifice 21 formed through the side of the valve core 14. An annular flange 22 extends radially 25 outwardly from the valve core 14 between the inlet and outlet orifices 18 and 21 and adjacent to the outlet orifice 21.

- 10 -

A stainless steel compression coil spring 23 acts between the annular flange 22 and the second sealing washer 13, urging the annular flange 22 into contact with the first sealing washer 11, such that the outlet 5 orifice 21 lies inside the first sealing washer 11 and is thereby isolated from the metering chamber 6. In this position, as shown in Figure 1, the inlet orifice 18 is located within the metering chamber 6. A flexible tube 24 is engaged within the stepped inlet 10 passage 16 and extends from the valve core 14 to the base of the canister 2 (as shown in Figure 1). Thus, the inlet orifice 18 is in communication with a region within the canister 2 adjacent to its base 12.

15 The cap 3 is firmly attached to the canister 2 by crimping and, thus, holds the assembly of the valve body moulding 4, valve core 14, coil spring 23, sealing washers 11 and 13 and sealing ring 10 in place as shown in Figure 1, with the sealing ring 10 and first sealing 20 washer 11 sufficiently compressed to seal the interior of the device 1 and prevent the egress of its contents.

Downward movement of the valve core, in the direction of arrow A, against the action of the spring 22 will 25 bring the outlet orifice 21 into the metering chamber immediately after the first orifice 18 has been sealed from the metering chamber 6 by the second sealing washer 13.

- 11 -

When filled with a composition in accordance with the present invention, as shown at 25, the device 1 will provide metered doses of the composition when used as follows. The device 1 should be held in the position 5 shown in Figure 1, so that the composition 25, by virtue of its pressure, enters the metering chamber 6 via the tube 24, the inlet passage 16 and the inlet orifice 18. Subsequent depression of the valve core 14, in the direction of arrow A, seals the inlet orifice 18 10 and hence the remainder of the canister 2, from the metering chamber 6 and opens the outlet passage to the metering chamber 6, via the outlet orifice 21. Since the composition 25 in the metering chamber 6 is pressurised with the propellant, it will be expelled 15 from the metering chamber 6 through the outlet orifice 21 and the outlet passage 19. If the valve core 14 is then allowed to return to the position shown in Figure 1, under the influence of the spring 22, the outlet orifice 21 is again sealed from the metering chamber 6 20 and the metering chamber 6 will be filled with pressurised composition 25 from the canister 2, via the tube 24, stepped inlet passage 16 and inlet orifice 18.

Example 1

25 A composition of glyceryl trinitrate with HFC-134a suitable for use in a device as described above is formulated from the following ingredients:-

| <u>Component</u> | <u>Mg/dose</u> | <u>percent w/w</u> | <u>g/can</u> |
|------------------|----------------|--------------------|--------------|
|------------------|----------------|--------------------|--------------|

- 12 -

|                       |       |      |       |
|-----------------------|-------|------|-------|
| Glyceryl trinitrate   | 0.4   | 0.7  | 0.099 |
| Ethanol 96% BP        | 7.6   | 13.2 | 1.866 |
| Peppermint oil Ph Eur | 0.8   | 1.4  | 0.205 |
| HFC-134a              | 48.2  | 84.7 | 12.02 |
| 5 Total               | 57.00 | 100  | 14.19 |

The ethanol and glyceryl trinitrate is obtained as a 5% glyceryl trinitrate solution in 96% ethanol BP from commercial sources. The peppermint oil is added to the 10 glyceryl trinitrate/ethanol solution and mixed thoroughly. 2.17g of the resulting solution is then placed in the canister 2 and the valve assembly, comprising the valve body moulding 4, first sealing washer 11, second sealing washer 13, spring 22, tube 15 23, and annular seal 10 are then sealed onto the canister 2 by crimping as shown in Figure 1 by the cap 3. The propellant (HFC-134a) is then added to the canister, by being forced through the valve core 14 at great pressure, and the complete device is then checked 20 for leaks. After the propellant has entered the canister it dissolves with the remaining portions of the composition.

In a preferred embodiment, the weight of each expelled 25 dose of the above formulation is between 51 and 63 milligrams, providing 0.4 milligrams of glyceryl trinitrate per dose. This embodiment should provide a minimum of 200 doses.

- 13 -

CLAIMS

1. A device for providing pharmaceutical doses,  
5 comprising a container, filled with a pharmaceutical  
composition including glyceryl trinitrate and 1,1,1,2-  
tetrafluoroethane (HFC-134a) or 1,1,1,2,3,3,3-  
heptafluoropropane (HFC-227) as a propellant, and valve  
means arranged for delivering aerosol doses of said  
10 pharmaceutical composition to the exterior of the  
container, wherein at least a portion of the device is  
formed from a polyester.

2. A device as claimed in claim 1, wherein the  
15 propellant is HFC-134a.

3. A device as claimed in claim 1 or claim 2, wherein  
the preparation further comprises a lower alkyl  
alcohol, preferably ethanol, or a pharmaceutically  
20 acceptable polyol, preferably propylene glycol,  
glycerol or polyethylene glycol.

4. A device as claimed in any one of claims 1-3,  
wherein the preparation further comprises a flavouring  
25 oil, preferably peppermint oil Ph Eur.

5. A device as claimed in claim 1, wherein the  
pharmaceutical composition comprises 75-95% w/w

- 14 -

propellant, an optional amount of 0.5-2% w/w of a flavouring oil, preferably peppermint oil Ph Eur, and 5-25% w/w of a combination of 2-8% w/w glycetyl trinitrate and 92-98% w/w of a lower alkyl alcohol, 5 preferably ethanol, or a pharmaceutically acceptable polyol, preferably propylene glycol, glycerol or polyethylene glycol.

6. A device as claimed in any of the preceding  
10 claims, wherein the valve means includes at least one component formed from a polyester.

7. A device as claimed in claim 6, wherein two relatively movable, preferably mutually slidable, valve  
15 components are formed from a polyester.

8. A device as claimed in claim 6, wherein said component is a metering chamber.

20 9. A device as claimed in claim 6, wherein said component is a valve core.

10. A device as claimed in any of the preceding claims, wherein the container includes a canister body  
25 comprising a polyester.

11. A device as claimed in claim 10, wherein the canister body is formed from metal lined with the

- 15 -

polyester.

12. A device as claimed in claim 1, wherein said portion is a canister cap or lining.

5

13. A device as claimed in any of the preceding claims, wherein the polyester is a polyalkylene benzene dicarboxylate.

10 14. A device as claimed in claim 13, wherein the polyester is a polyalkylene terephthalate.

15. A device as claimed in claim 14, wherein the polyester is a polybutylene terephthalate.

15

16. A device as claimed in claim 3 or claim 5 wherein the composition comprises ethanol.

17. A device as claimed in any of the preceding  
20 claims, for use in treating angina pectoris.

18. Use of a polyester in contact with a composition comprising glyceryl trinitrate, HFC-134a and/or HFC-  
227.

25

19. A use as claimed in claim 18, wherein said composition is a pharmaceutical composition as claimed in any one of claims 21-24.

- 16 -

20. A use as claimed in claim 18 or claim 19, wherein  
the polyester is as defined in any one of claims  
12-14.

5

21. A pharmaceutical composition for use in a device  
as claimed in any of claims 1-17 comprising 75-95% w/w  
1,1,1,2-tetrafluoroethane (HFC-134a) or 1,1,1,2,3,3,3-  
heptafluoropropane (HFC-227) as a propellant, an  
10 optional amount of 0.5-2% w/w of a flavouring oil, and  
5-25% w/w of a combination of 2-8% w/w glycetyl  
trinitrate and 92-98% w/w of a lower alkyl alcohol or a  
pharmaceutically acceptable polyol.

15 22. A pharmaceutical composition as claimed in claim  
21, wherein the flavouring oil is peppermint oil Ph  
Eur.

23. A pharmaceutical composition as claimed in claim  
20 20, wherein the lower alcohol is ethanol.

24. A pharmaceutical composition as claimed in claim  
21, wherein the pharmaceutically acceptable polyol is  
propylene glycol, glycerol or polyethylene glycol.

25

1 / 1




FIG. 1

SUBSTITUTE SHEET (RULE 26)

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 96/02174

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC 6 A61K9/00 A61K9/12 A61K31/21 B65D83/38

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

| Category * | Citation of document, with indication, where appropriate, of the relevant passages   | Relevant to claim No. |
|------------|--|-----------------------|
| Y          | DE,A,40 38 203 (KALI-CHEMIE PHARMA GMBH) 4 June 1992   | 1-3,6,<br>13-18       |
| X          | see the whole document   | 21                    |
| Y          | EP,A,0 471 468 (FISONS PLC) 19 February 1992   | 1-3,6,<br>13-18       |
|            | see the whole document   |                       |
| A          | EP,A,0 342 269 (SUNSTAR KABUSHIKI KAISHA) 23 November 1989<br>see page 4, line 50 - page 5, line 28<br>see page 8, line 58 - page 9, line 5<br>see example 9 | 1,3,6,<br>10,13-16    |
| A          | EP,A,0 461 505 (SCHWARZ PHARMA AG) 18 December 1991<br>see page 3, line 25 - line 30   | 1,3                   |
|            |  | -/-                   |

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

\* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*&\* document member of the same patent family

1

Date of the actual completion of the international search

19 December 1996

Date of mailing of the international search report

14.01.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+ 31-70) 340-3016

Authorized officer

Puetz, C

## INTERNATIONAL SEARCH REPORT

Internat'l Application No

PCT/GB 96/02174

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|----------|--|-----------------------|
| A        | DE,A,32 46 081 (G.POHL-BOSKAMP GMBH) 14<br>June 1984<br>see example 1<br>-----     | 1,4                   |

1

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 96/02174

| Patent document cited in search report | Publication date | Patent family member(s) |          | Publication date |
|--|------------------|-------------------------|----------|------------------|
| DE-A-4038203                           | 04-06-92         | NONE                    |          |                  |
| EP-A-471468                            | 19-02-92         | AT-T- 114980            | 15-12-94 |                  |
|  |                  | DE-D- 69105663          | 19-01-95 |                  |
|  |                  | DE-T- 69105663          | 18-05-95 |                  |
| EP-A-342269                            | 23-11-89         | JP-A- 1294606           | 28-11-89 |                  |
|  |                  | AU-B- 619217            | 23-01-92 |                  |
|  |                  | AU-A- 2460488           | 23-11-89 |                  |
|  |                  | CA-A- 1337393           | 24-10-95 |                  |
|  |                  | CN-A- 1037836           | 13-12-89 |                  |
|  |                  | DE-D- 3883753           | 07-10-93 |                  |
|  |                  | DE-T- 3883753           | 09-12-93 |                  |
|  |                  | ES-T- 2014960           | 16-11-94 |                  |
|  |                  | US-A- 4985234           | 15-01-91 |                  |
|  |                  | US-A- 5078987           | 07-01-92 |                  |
| EP-A-461505                            | 18-12-91         | DE-A- 4018919           | 19-12-91 |                  |
|  |                  | AT-T- 118685            | 15-03-95 |                  |
|  |                  | DE-D- 59104654          | 30-03-95 |                  |
|  |                  | ES-T- 2068428           | 16-04-95 |                  |
|  |                  | IE-B- 65420             | 18-10-95 |                  |
|  |                  | JP-A- 4243823           | 31-08-92 |                  |
|  |                  | US-A- 5370862           | 06-12-94 |                  |
| DE-A-3246081                           | 14-06-84         | NONE                    |          |                  |

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**

**THIS PAGE BLANK (USPTO)**